The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said …
For many investors, the weight loss drug boom has boosted Danish pharmaceutical giant Novo Nordisk ‘s appeal this year — but one investment bank has reservations. “Over the coming year, …
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to …
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to …
Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight …
Many stocks have seen massive rallies this year as investors turned bullish on sectors like Big Tech, biotech, electric vehicles, and weight loss drugs. As the year-end nears, CNBC Pro …
It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Stocks of both pharmaceutical companies have rallied this year. Shares in …
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is …
The Wall Street bronze Bull looks out to an empty Broadway in Lower Manhattan, New York, on Aug. 28, 2011, as Hurricane Irene hits the city and tri-state area with …
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain …